This multicenter, first-in-human study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of the anti-CS1 monoclonal antibody elotuzumab. A standard 3+3 design was utilized to determine maximum tolerated dose (MTD); dose-limiting toxicities were assessed during cycle 1.
INTRODUCTION
Multiple myeloma (MM) is an incurable malignancy arising from postgerminal mature B cells, characterized by an excess of monotypic plasma cells in the bone marrow and elevated levels of monoclonal immunoglobulins in the serum and/or urine. 1 Common clinical sequelae include lytic bone lesions, fractures, myelosuppression, and renal failure. In the United States, the estimated annual diagnosed incidence is 20,000, with a prevalence of approximately 62,000 as of 2007. [2] [3] Multiple myeloma accounts for 15% of all hematologic malignancies and 2% of all malignancies. 4 Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival (OS) and event-free disease periods in MM, [5] [6] [7] although relapses are inevitable. Newer therapeutic agents such as bortezomib, thalidomide, and lenalidomide have demonstrated clinical benefit in patients with newly diagnosed [8] [9] [10] [11] [12] [13] and relapsed or refractory disease. 5, [14] [15] Despite these therapeutic advances, long-term control of relapsed/refractory MM remains elusive for most patients. Progressive disease that is resistant to both immunomodulatory drugs and bortezomib is associated with a particularly poor prognosis. 16 As such, there remains an important need for additional novel therapies to augment existing first-generation agents and continue to improve patient outcome.
Elotuzumab is a humanized monoclonal IgG1 antibody directed against human CS1 (also known as CD2 subset-1, SLAMF7, CRACC, and CD319), a cell surface antigen glycoprotein that is highly expressed on MM cells and normal 17 Elotuzumab has significant in vivo antitumor efficacy in severe-combined immunodeficient (SCID) mice MM xenograft models. [17] [18] [19] Data obtained from these models and in vitro studies using human peripheral blood mononuclear cells formed the basis for the selection of the doses and schedule used in the current study.
This study was conducted to determine the maximum tolerated dose (MTD) of elotuzumab up to a maximum planned dose (MPD) of 20 mg/kg when given as a monotherapy, and to characterize the safety, pharmacokinetics (PK), and preliminary efficacy in adults with advanced MM and limited treatment options.
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METHODS

Study Design
This was a multicenter, open-label, dose-escalation phase 1 study designed to evaluate elotuzumab administered by intravenous (IV) infusion at up to 6 dose levels (0. Elotuzumab was prepared according to protocol specifications and infused at a rate of 2 mL/min with calibrated infusion pumps. Originally, pretreatment with an antihistamine and acetaminophen was optional in patients who experienced any infusion reaction. Following the observation of infusion-related AEs, the protocol was amended to require that all patients receive an antihistamine and acetaminophen prior to and during each infusion. In addition, unless contraindicated, an IV corticosteroid was required to be administered prior to the first dose in 20 mg/kg elotuzumab cohort.
The study was conducted in compliance with principles of the International Conference on Harmonisation guidelines on Good Clinical Practice, the Declaration of Helsinki, and the applicable local and national regulations. All patients provided written informed consent. 20 which included measurements of MM plasma cell levels in the bone marrow, serum and urine M-protein, and serum and urinary free light chain.
Patients were evaluated for disease activity and survival up to 6 months after their last dose.
Pharmacokinetics
Blood samples were collected throughout the study and until 60 days post-dose for the determination of PK parameters. 
Immunogenicity
Immunogenicity testing was performed on samples collected up to 60 days post treatment using a tiered approach. All samples were initially screened for the presence of antibodies to elotuzumab (antidrug antibody, ADA) using an electrochemiluminescent bridging assay. The screening assay cut point 21 was set using baseline samples from patients in the study and additional drug-naïve MM serum. Screen-positive samples were titered and then tested in a confirmatory assay by preincubating with soluble, excess elotuzumab to determine if a significant decrease in signal was observed. Confirmed positive samples were then tested in a cell-based neutralizing antibody (NAb) assay. The
NAb assay format uses ruthenium labeled elotuzumab that binds CS1 on cells in the presence of patient's baseline serum; if NAbs are present at later time points, a percent inhibition in signal relative to the baseline response can be observed.
A sample was considered NAb positive when the relative percent inhibition was greater than or equal to 17.41% (cut-off based on the variation observed in the assay during validation).
Pharmacodynamics
CS1 Saturation Assays and Lymphocyte Counts
For personal use only. on April 21, 2017 . by guest www.bloodjournal.org From Whole blood and bone marrow samples collected from patients at protocoldefined time points were shipped by overnight courier to Esoterix Clinical Trial Services (Brentwood, TN, USA). Percentage and absolute numbers of peripheral blood T, B, and NK cells were analyzed using the BD TruCOUNT™ assay (BD Biosciences, Franklin Lakes, NJ, USA). CS1 saturation was measured using fluorescently labeled elotuzumab in a flow cytometric assay. CS1 expression was assessed using a fluorescently labeled monoclonal antibody that does not compete with elotuzumab for binding to CS1. CS1 saturation and expression assays were performed on peripheral NK and CD8+ T cells and on bone marrow NK cells, as well as CD38+ and CD138+ putative myeloma cells.
Cytokines
Serum levels of interferon-inducible protein 10 (IP-10), a chemokine that stimulates migration of activated T cells and NK cells, were measured in a multiplexed assay using LINCO kits on the Luminex platform (Linco Research, Inc, St. Charles, MO, USA). Samples were collected on the same day prior to elotuzumab treatment and at 2 and 4 hours following elotuzumab dosing, and then frozen until the assay was performed.
Statistical Methods
The primary objective of the study was to evaluate the safety and identify the MTD of elotuzumab, to an MPD of 20 mg/kg, in patients with advanced MM.
Secondary objectives were to evaluate the PK, immunogenicity, and objective The modified intent-to-treat population was defined as patients who have received at least 1 dose of study medication. A patient was considered DLT evaluable if the patient had received 2 doses of study medication or had experienced a DLT resulting from the first treatment.
Patient Eligibility
Patients eligible for the study included adults aged 18 years or older who had a diagnosis of advanced MM and prior treatment with at least 2 prior MM therapies.
Patients were also required to meet the following criteria: ECOG performance status score of 0-2; measurable M component in serum (≥0.5 g/dL) and/or urine (≥0.2 g excreted in a 24-hour collection sample); adequate bone marrow function (defined as absolute neutrophil count >1000 cells/mm Patients were ineligible for this study if they had met any one of the following criteria: life expectancy of less than 3 months; prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the patient had been disease-free for at least may hinder or confuse follow-up evaluation; hypersensitivity to recombinant proteins or excipients in the investigational agent; platelet transfusion within 72 hours of obtaining screening platelet count; and any condition that in the investigator's opinion made the patient unsuitable for study participation.
In order to mitigate infusion reactions, the original protocol was amended to include a premedication regimen; patients in 20 mg/kg elotuzumab cohort received premedication of 50 mg methylprednisolone, diphenhydramine and acetaminophen prior to the first elotuzumab dose only. Diphenhydramine and acetaminophen were suggested prior to each subsequent infusion. Another amendment allowed patients who demonstrated stable disease (SD) or better at Day 56 to receive additional doses of elotuzumab.
RESULTS
Study Population
The study was conducted between November 2006 and August 2009 at 8 sites in the United States and 1 in France. Study disposition is detailed in Table 1 . Fiftyone patients were screened of which 35 were enrolled into 6 dosing cohorts: 3 in the 0.5-mg/kg cohort, 4 in the 1.0-mg/kg cohort, 6 in the 2.5-mg/kg cohort, 4 in the 5.0-mg/kg cohort, 4 in the 10-mg/kg cohort, and 14 in the 20-mg/kg cohort.
Thirty-four patients received study treatment. One patient was enrolled in the 10-mg/kg cohort but was withdrawn from the study by the investigator before receiving study medication after developing severe neuropathy. One patient each in the 1.0-mg/kg and 5.0-mg/kg cohorts withdrew from the study due to disease progression after receiving 1 or 2 doses. In each of these 3 cohorts, another patient was enrolled as a replacement.
Patient demographics and disease characteristics are presented in Table 2 .
Most patients were Caucasian with a median age of 64.5 years and a median of 4.5 prior MM treatments. All patients had received prior immunomodulatory agents; 28 (82.4%) and 27 (79.4%) had received lenalidomide and thalidomide, respectively. Twenty-eight (82.4%) patients had received prior bortezomib.
Of the 34 patients treated, 25 completed the initial treatment phase, and 8 were subsequently retreated. A median of 4 infusions were administered (range, 1-12). Reasons for treatment cessation are detailed in Table 1 . The majority of For personal use only. on April 21, 2017 . by guest www.bloodjournal.org From patients discontinued treatment due to disease progression. In addition to the 2 patients who discontinued treatment due to DLTs (detailed below), 1 patient in the 0.5-mg/kg cohort discontinued due to unrelated AEs of headache and congestive cardiac failure, which required hospitalization. Sixteen patients completed the 6-month post-treatment follow-up period.
Safety
Two patients experienced DLTs during their first cycle of treatment; 1 patient in the 2.5-mg/kg cohort had an episode of Grade 3 increased serum creatinine, and 1 in the 20-mg/kg cohort experienced a Grade 3 hypersensitivity reaction that resolved spontaneously within 24 hours. Subsequently, both patients discontinued study treatment. As a consequence the 2.5-mg/kg cohort was expanded to 6 patients. An MTD was not reached in this study up to the MPD of 20 mg/kg.
Adverse Events
Overall, 30 patients (88.2%) reported treatment-emergent AEs. The most frequent treatment-emergent AEs, regardless of attribution to study medication, included chills, fatigue, pyrexia, cough, headache, anemia, nausea, and back pain. Most events were Grade 1 or 2 in severity. Eighteen patients (52.9%) experienced AEs attributed to elotuzumab. Four patients died during the course of the study. One patient died from renal failure 20 days following last elotuzumab dose and 13 days following discontinuation from study due to disease progression. Three patients died due to disease progression. The events leading to death were assessed as not related to study drug.
Prior to the implementation of the revised infusion management guidelines, 13 of 25 treated patients experienced infusion reactions, which with 1 exception (Grade 3 hypersensitivity reaction) were Grade 1 or 2 in severity. In total, 5 patients had at least 1 infusion interrupted, discontinued, or rate of infusion reduced in response to an infusion reaction. Most frequent infusion reactions 
Efficacy
Response
Overall, no objective responses were observed during the course of the study while patients were receiving treatment. Using the EBMT myeloma response criteria, 9 patients (26.5%) were classified as having SD; the remaining patients had PD.
Pharmacokinetics, Pharmacodynamics, and Immunogenicity
PK parameters following the first and fourth doses are summarized in Table 4 . Overall, 31 patients were tested for immunogenicity; of these, 12 of 31 (39%) were positive for ADAs, and 11 of 12 of these ADA-positive samples were also NAb-positive. The incidence of immunogenicity varied across dose groups (Table 5) . Fewer positive responses (3 of 16) were observed for patients in the higher dose groups of 10 mg/kg and 20 mg/kg in comparison to the lower dose groups (9 of 15). PK analysis suggested that ADA responses seen at lower doses had a more noticeable impact on PK than those seen at higher doses. In the patients with a positive ADA response in the lower dose groups (≤5 mg/kg), serum trough concentrations were lower compared to those who had no ADA response. ADA responses were minimized at the 10-mg/kg and 20-mg/kg doses and CS1 receptors on the target cells were saturated, even when a NAb This study demonstrated that elotuzumab was generally well-tolerated at doses sufficient to achieve biologically relevant serum levels and near-complete saturation of the glycoprotein target CS1. Dosing at either 10 mg/kg or 20 mg/kg resulted in target saturation (≥95% of CS1 receptors) without dose-limiting toxicity.
With the exception of 1 case of acute renal failure that was attributed to elotuzumab, the treatment-related toxicity observed was largely limited to Grade 1 and 2 infusion reactions that usually occurred with the first infusion of No objective myeloma responses were seen in this heavily pretreated patient population, despite plasma cell target saturation at the higher elotuzumab doses For personal use only. on April 21, 2017. by guest www.bloodjournal.org From studied. In preclinical models, elotuzumab exerted its antimyeloma effect primarily via NK cell-mediated ADCC. 17 It is conceivable that less-heavily pretreated patients would have better NK cell function, possibly resulting in a more robust ADCC response.
37
Both bortezomib and lenalidomide have been shown to enhance elotuzumabmediated anti-myeloma activity in preclinical models. [18] [19] 38 Given this effect and the non-overlapping toxicity of elotuzumab with either of these agents, there is a strong rationale for exploring combination therapy. Clinical trials combining elotuzumab at doses of 10 mg/kg and 20 mg/kg with each of these drugs are being conducted and have shown evidence of activity.
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